Navigation Links
Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach
Date:9/14/2009

BOSTON, Sept. 14 /PRNewswire/ -- The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

The scientific program will kick off with an opening plenary session, "Personalized Medicine: The Dawn of a New Era," today at 8:30 a.m. This session will be anchored by Journalist David Duncan, author of The Experimental Man: What one man's body reveals about his future, your health, and our toxic world.

Following the Opening Plenary will be simultaneous sessions with presentations by national and international heart failure experts, scientists, and allied health care professionals. Many will focus on the progressive treatments for heart failure and the increased risk faced by patients.

"This year's conference will present exciting new information," said Dr. Douglas Mann, President, HFSA. "Leaders in the field will discuss causes and treatment of heart failure and the important socio-economic issues surrounding this condition."

Other scientific meeting sessions that address important heart failure issues include:

  • Clinical Use of Stem Cells in the Heart: What Have We Learned?
  • Cardiovascular Disease: The Hidden Killer in Adult Survivors of Childhood Cancer
  • Is the Physical Exam Obsolete?
  • New Development in Gene Therapy for Heart Failure

Late Breaking heart failure Clinical Trials to be presented include:

  • Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of IMPROVE HF
  • Reduction in the Risk of Heart Failure with Preventive Cardiac Resynchronization Therapy: MADIT-CRT
  • Effects of Rolofylline, A Selective Adenosine A1 Antagonist in Patients Hospitalized for ADHF and Renal Impairment: Findings from the PROTECT study

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may also follow news from the 2009 annual meeting on Twitter #hfsa.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggest the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,700 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.


'/>"/>
SOURCE The Heart Failure Society of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):